What is Protara Therapeutics, Inc.'s market cap?

Protara Therapeutics, Inc. (TARA) has a market capitalization of $227.1M and trades on NASDAQ.

Who are Protara Therapeutics, Inc.'s competitors?

Protara Therapeutics, Inc.'s key competitors include ImmunityBio, Inc., CG Oncology Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.

Who does Protara Therapeutics, Inc. partner with?

Protara Therapeutics, Inc.'s notable partners include Chugai Pharmaceutical Co., Ltd., The University of Iowa, The Feinstein Institute for Medical Research, and others.

What subsidiaries does Protara Therapeutics, Inc. have?

Protara Therapeutics, Inc.'s subsidiaries include ArTara Subsidiary, Inc..

Where is Protara Therapeutics, Inc. headquartered?

Protara Therapeutics, Inc. is headquartered in United States of America and employs approximately 27 people. It has been publicly traded since 2020.

Protara Therapeutics, Inc.

TARA

Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases.

Market cap

$227.07M+85.1%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$0.31Beat by $0.05

Read the full report

Next report

Aug 10, 2026 (In 1 week)

EPS estimate-$0.33

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

ImmunityBio, Inc.$7.3B+213%

CG Oncology$6.5B+229%

Immunome$2.6B+171%

ArriVent BioPharma, Inc.$1.4B+82.9%

Protara Therapeutics, Inc.$227.1M+75.7%

By revenue growth

CG Oncology+666%

ImmunityBio, Inc.+352%

Johnson & Johnson+8.1%

Merck & Co.+2.9%

Pfizer+1.4%

Immunome-63.3%

By net margin

Johnson & Johnson21.48%-3.5pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

ImmunityBio, Inc.-606.15%+704pp

CG Oncology-3,682.61%+12,263pp

Immunome-5,593.85%-3,719pp

Profile

Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. The company specializes in applying modern scientific and manufacturing advancements to established biological mechanisms to create de-risked clinical programs. Its lead development efforts center on cell-based immunopotentiators and substrate replacement therapies for high unmet need indications.

Competitive position

Clinical-stage developer leveraging a validated biological mechanism (OK-432) with exclusive rights in major global territories outside of Japan and Taiwan.

GeographiesUnited States, Global (excluding Japan and Taiwan for TARA-002)

Customer segmentsPatients, Healthcare providers, Specialized medical centers

Business modelR&D, Biotechnology drug development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Chugai Pharmaceutical (cell bank and technical materials), Academic research institutions

CustomersSpecialized medical centers, Hospitals, Urologists, Pediatric surgeons

CountryUnited States of America

Listed2020

Employees27.0

CEOJesse Shefferman

SectorHealthcare

IndustryBiotechnology

Websiteprotaratx.com

FilingsSEC EDGAR

Questions, answered.

What is Protara Therapeutics, Inc.'s market cap?: Protara Therapeutics, Inc. (TARA) has a market capitalization of $227.1M and trades on NASDAQ.
Who are Protara Therapeutics, Inc.'s competitors?: Protara Therapeutics, Inc.'s key competitors include ImmunityBio, Inc., CG Oncology Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
Who does Protara Therapeutics, Inc. partner with?: Protara Therapeutics, Inc.'s notable partners include Chugai Pharmaceutical Co., Ltd., The University of Iowa, The Feinstein Institute for Medical Research, and others.
What subsidiaries does Protara Therapeutics, Inc. have?: Protara Therapeutics, Inc.'s subsidiaries include ArTara Subsidiary, Inc..
Where is Protara Therapeutics, Inc. headquartered?: Protara Therapeutics, Inc. is headquartered in United States of America and employs approximately 27 people. It has been publicly traded since 2020.